The company has entered into a binding agreement with Molteni Farmaceutici regarding exclusive rights to commercialize BupiZenge in Europe.

The post OncoZenge in agreement for the commercialization of BupiZenge in Europe appeared first on NLS.

Manufacturers’ perspectives on mechanisms for coping with uncertainty.

The post Holding a steady course through troubled waters appeared first on NLS.

The Board of Directors of Flerie and the Board of Directors of Toleranzia have adopted a plan to join forces through a statutory merger between the companies in accordance with the Swedish Companies Act.

The post Flerie and Toleranzia agree on merger plan to take Toleranzia private appeared first on NLS.

A meeting organized by PharmaLex and the Life Science Cluster in Norway on February 27 2025 brought together experts eager to share and learn more about the European Union’s Health Technology Assessment Regulation (HTAR), its requirements and challenges, and its adoption and impact.

The post Brain & Breakfast meeting in Norway discussed EU HTAR implications  appeared first on NLS.

Immunovia has announced additional results from the VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially. 

The post Immunovia provides further positive data from the VERIFI study appeared first on NLS.

Elypta has announced that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented today in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.

The post New findings about Elypta’s urine test in kidney cancer follow-up appeared first on NLS.

Novo Nordisk and the United Laboratories International Holdings Limited (TUL)'s wholly-owned subsidiary, The United Bio-Technology (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

The post Novo Nordisk gains rights to China-based The United Laboratories’ ‘triple G’ obesity drug appeared first on NLS.

AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide.

The post AstraZeneca to invest USD 2.5 billion in R&D centre in Beijing appeared first on NLS.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101), an anti-HER2 monoclonal antibody, for the treatment of gastric cancer.

The post Alligator Bioscience announces FDA Orphan Drug designation appeared first on NLS.

Notwithstanding political ‘hiccups,’ the US will remain the most favored market for Nordic life science companies, say experts.

The post The changing US regulatory environment: Amid Chaos, Signs of Opportunity appeared first on NLS.